LENZ THERAPEUTICS, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
LENZ THERAPEUTICS, INC. (LENZ) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $51.00 million as of 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Notes › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2023-11-13
- 2023-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $51.00M.
- 2023-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $118.20M.
- 2023-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $194.30M.
- 2022-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $220.50M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2023-09-30 | $51.00M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $118.20M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $194.30M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $220.50M 10-K · filed 2023-03-20 |
| 2022-09-30 | $235.30M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $247.10M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $154.10M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |